Enterprise Value

337.4M

Cash

176.3M

Avg Qtr Burn

-11.64M

Short % of Float

25.97%

Insider Ownership

8.67%

Institutional Own.

71.96%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
CABA-201 (4-1BB CD19-CAR T) Details
Systemic lupus erythematosus, Lupus nephritis

Phase 1/2

Data readout

CABA-201 (4-1BB CD19-CAR T) Details
Immune-mediated necrotizing myopathy, Anti-synthetase syndrome, Idiopathic inflammatory myopathy / myositis, Dermatomyositis

Phase 1/2

Data readout

Phase 1/2

Initiation

Phase 1/2

Initiation

MuSK-CAART Details
Myasthenia gravis, Autoimmune disease

Phase 1

Data readout

DSG3-CAART Details
Mucosal Pemphigus Vulgaris

Phase 1

Data readout